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Abstract: 
Ramipril is an anti-hypertensive drug, a category of ACE inhibitor that inhibit  the actions of angiotensin converting 
enzyme (ACE), thereby decreasing the production of  angiotensin II and  decreasing the breakdown of bradykinin. 
The decrease in an enzyme angiotensin II results in relaxation of arteriole smooth muscle leading to a lowering the 
total peripheral resistance, reducing blood pressure(BP) as the blood is pumped through widened. Ramipril, a 
precursor or prodrug, is converted to the active metabolite ramiprilat by carboxylesterase. It is mostly excreted by 
the kidneys. Its half-life is 3-16 hours and is prolonged by heart and liver failure, as well as kidney failure. The 
medication used alone or in combination with other medications to treat high blood pressure.  The drug is also used 
to reduce the risk of stroke and heart attack in patients at risk for these types of problems and to improve survival in 
patients with heart failure after a heart attack. 
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INTRODUCTION: 
Hypertension, which affects one in four adults 
worldwide, is an important cause of cardiovascular 
morbidity and mortality, and antihypertensive 
treatment is a common therapeutic intervention. 
Clinical guidelines have recommended threshold 
levels for the implementation of antihypertensive 
therapy, typically based on blood pressure levels 
assessed by the physician in an office environment. 
Increasingly, however, it is being recognized that 
such ‘in-clinic’ measurements do not identify 
accurately variations in daily activity and their impact 
on blood pressure. Such measurements can, therefore, 
miss true hypertension. Exact prevalence of so-called 
‘reversed white-coat hypertension’, ‘masked 
hypertension’, or ‘white-coat normotension’ is 
difficult to establish, but four studies found 
incidences of between 9% and 23%. Masked 
hypertension carries an increased cardiovascular risk 
compared with the prognosis in individuals with 
well-controlled home or ambulatory blood pressure. 
In the elderly, the cardiovascular risk in those with 
masked hypertension was equal to that in those with 
sustained hypertension[1-6]. 
 
 
 
   Structure of Ramipril 
              
2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-
phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-
hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic 
acid. 
Pharmacokinetic data of Ramipril 
S.no Pharmacokinetic 
parameters 
value 
1 Bioavailability 28% 
2 Protein binding Ramipril (73%) 
Ramiprilat 
(56%) 
3 Metabolism Hepatic 
4 Biological half –life 2 – 4 hrs 
5 Excretion Renal (60%) 
Fecal (40%) 
 
Chemical data 
1 Formula C23H32N2O5 
2 Molecular 
weight 
416.511 g/mol 
3 Melting point 109 °C (228 °F) 
Mechanism of action 
ACE inhibitors inhibit the actions of angiotensin 
converting enzyme (ACE), thereby lowering the 
production of angiotensin II and decreasing the 
breakdown of bradykinin. The decrease in 
angiotensin II results in relaxation of arteriole smooth 
muscle leading to a decrease in total peripheral 
resistance and reducing blood pressure as the blood is 
pumped through widened vessels. Its effect on 
bradykinin is responsible for the dry cough side 
effect. 
 
 Adverse effects 
Mouth dryness in the early stages 
Dizziness and light-headedness due to low blood 
pressure. 
Chest pain. 
Shakiness 
Fatigue, especially in the early stages. 
 Nausea  
Dry cough 
Fainting 
Signs of infection (example- fever, chills, persistent 
sore throat) 
Neutrogena (low white blood cells) 
Impotence (erectile dysfunction) 
 
Warnings and Precautions:  
1) Use with caution in patients with history of an 
allergic reaction which included swelling of 
lips/tongue/face/throat (angioedema). Before using 
the medicine, tell your pharmacist or doctor your 
medical history, especially liver disease, kidney 
disease, heart problems, diabetes (poorly controlled), 
high blood levels of potassium, stroke, and severe 
dehydration. 
2) It may cause lightheadedness, dizziness, or 
fainting;-Alcohol, hot water, exercise, or fever may 
increase these effects. Get up slowly from bed. 
3) It may cause a serious side effect called 
angioedema with symptoms of swelling of the hands, 
eyes ,lips, face, throat or tongue: difficulty 
swallowing or breathing: or   hoarseness 
4) It may affect your blood sugar. Check blood sugar 
levels closely. 
5)  Monitoring the kidney function before and during 
treatment. 
6)  Regular monitoring of white blood cells in patient 
with vascular collagen disorder is recommended. 
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 Other Precautions:  
Excessive sweating, diarrhea or vomiting, 
dehydration may increase the risk of low blood 
pressure (low BP). So monitor blood pressure 
regularly. 
 
When it is not to be taken (Contraindications):  
Contraindicated in patients with  
1) Hypersensitivity, 
2) Bilateral renal artery stenosis (narrowing of the 
arteries going to the kidney)  
3) A single kidney with unilateral renal artery 
stenosis, 
4) Pregnancy and breastfeeding. 
5)   Aortic stenosis or outflow tract obstruction. 
 
Dosage & When it is to be taken (Indications):  
1) Heart failure- Initial dose: 1.25 mg once 
daily.(Max: 10 mg/day.) 
  
2)  Myocardial infarction (Heart Attack) - Start 3-
10 days after infarction. Initial dose:    2.5 mg 
twice daily after 2 days, then 5 mg twice daily. --
Maintenance dose: 2.5-5 mg twice daily. 
  
    3)PO- Hypertension- Initial dose: 1.25 mg at 
bedtime. -- Maintenance dose: 2.5-5 mg/day as a 
single dose, up to 10 mg/day if needed. 
 
 
TRADE NAMES/BRAND NAMES (RAMIPRIL) 
IN INDIA 
 
S.no Brand name/Trade name 
(Ramipril) 
1 Cardac-1.25 mg 
2 Ramil-  1.25 mg 
3 Telmisat-R 
4 Tazloc-R 
5 Ramipro 
6 Ramicard 
7 Ramilace 
8 Corpril 
9 Ramilor 
10 Ramihart 
11 Ramizyl 
12 BB Best-R 
13 Omyl-R 
14 Hopace-AM 
15 Altace 
 
What is ramipril used for? 
1) High blood pressure (hypertension). 
2) Heart failure. 
3) Improving survival in people who have heart 
failure after suffering heart attack. 
4) Reducing the risk of heart attack, stroke and 
death due to heart disease, in people with any of 
the following conditions. 
A) A history of heart disease, for example, a 
people who have had angina, heart attack, or a 
previous surgical procedure to improve blood 
supply to the heart, e.g heart bypass (coronary 
artery bypass graft-CABG). 
B) A history of stroke 
C) Poor blood circulation in the hands or feet due 
to hardening of the arteries(peripheral vascular 
disease) 
D) Diabetes plus one or more of the following risk 
factors - high blood pressure, high total 
cholesterol levels, low HDL cholesterol levels, 
smoking or protein in the urine. 
5) Treating kidney disease or delaying worsening of 
kidney disease (nephropathy) in people either with or 
without diabetes. 
 
Storage Conditions:  
Store at 25 c. Store it in an airtight container and 
keep away from children. 
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